Animal models for Parkinson's disease.

Area of Science:

• Neuroscience
• Neurology
• Pharmacology

Background:

• Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by dopamine deficiency due to substantia nigra neuron loss.
• Despite extensive research since the 1960s, a cure for PD remains elusive, though symptom management is possible.
• Key challenges in developing neuroprotective therapies stem from an incomplete understanding of PD's molecular pathogenesis, including protein misfolding and ubiquitin-proteasome pathway dysfunction.

Purpose of the Study:

• To review and describe various animal models utilized in the assessment of novel therapeutic treatments for Parkinson's disease.
• To highlight the utility of these models in understanding the molecular mechanisms underlying PD pathogenesis.
• To underscore the importance of animal models in screening potential antiparkinsonian agents.

Main Methods:

• Utilized neurotoxic models, such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), to investigate dopaminergic neuron cell death.
• Established and employed cellular and animal models based on genetic mutations linked to PD (LRRK2, α-synuclein, parkin, DJ-1, PINK1).
• Described the synthesis and screening of novel compounds for antiparkinsonian activity in various animal models.

Main Results:

• Neurotoxic and genetic models have been instrumental in elucidating the molecular pathways of cell death in dopaminergic neurons.
• These models aid in the development of strategies to mitigate disease progression and long-term pathological outcomes.
• Research using these models provides critical insights into the pathogenesis of Parkinson's disease.

Conclusions:

• Animal and cellular models are indispensable tools for advancing the understanding of Parkinson's disease.
• These models facilitate the evaluation of novel therapeutic strategies aimed at controlling PD symptoms and potentially slowing disease progression.
• Continued research using diverse models is essential for identifying effective antiparkinsonian treatments.